بروبوفول

The drug is indicated for use as an anesthetic as follows: As a single injection to provide general anesthesia for procedures lasting up to 5 minutes; for induction and maintenance of general anesthesia using incremental doses to effect; for induction of general anesthesia where maintenance is provided by inhalant anesthetics.

Adequate data concerning safe use of propofol in pregnant and breeding dogs have not been obtained. Doses may need adjustment for geriatric or debilitated patients.

Rapanofal®

For induction of anesthesia. For maintenance of general anesthesia by intermittent bolus injections for short procedures. For induction of general anesthesia where maintenance is provided by inhalant anesthetics.

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Administer by intravenous injection only. Rapid bolus administration (induction or maintenance) or accidental overdosage of propofol may cause undesirable cardiorespiratory depression including hypotension and oxygen desaturation. Respiratory arrest (apnea) could occur. When using propofol, dogs should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. The use of propofol in pregnant and breeding dogs has not been evaluated. Propofol crosses the placenta and, as with other general anesthetic agents, the administration of propofol may be associated with neonatal depression. Propofol has not been evaluated in dogs less than 10 weeks of age

PropoFlo™ 28

For induction of anesthesia. For maintenance of general anesthesia for up to 20 minutes. For induction of general anesthesia where maintenance is provided by inhalant anesthetics.

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Administer by intravenous injection only. Rapid bolus administration (induction or maintenance) or accidental overdosage of propofol may cause undesirable cardiorespiratory depression including hypotension and oxygen desaturation. Respiratory arrest (apnea) could occur. When using propofol, dogs should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. The use of propofol in pregnant and breeding dogs has not been evaluated. Propofol crosses the placenta and, as with other general anesthetic agents, the administration of propofol may be associated with neonatal depression. Propofol has not been evaluated in dogs less than 10 weeks of age

PropoFlo™

For the induction and maintenance of anesthesia and for induction followed by maintenance with an inhalant anesthetic.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using propofol, patients should be continuously monitored and facilities for the maintenance of a patient airway, artificial ventilation, and oxygen supplementation must be immediately available.

PropoClear™

The drug is indicated for use as an anesthetic as follows: As a single injection to provide general anesthesia for short procedures, for induction and maintenance of general anesthesia using incremental doses to effect, and for induction of general anesthesia where maintenance is provided by inhalant anesthetics.

Adequate data concerning safe use of propofol in pregnant and breeding cats have not been obtained. Doses may need adjustment for geriatric or debilitated patients. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Rapanofal®

For the induction and maintenance of anesthesia and for induction followed by maintenance with an inhalant anesthetic.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using propofol, patients should be continuously monitored and facilities for the maintenance of a patient airway, artificial ventilation, and oxygen supplementation must be immediately available.

PropoClear™

Propofol injectable emulsion is an anesthetic injection for use in dogs and cats as follows: 1. As a single injection to provide general anesthesia for short procedures. 2. For induction and maintenance of general anesthesia using incremental doses to effect. 3. For induction of general anesthesia where maintenance is provided by inhalant anesthetics. Induction of general anesthesia will usually be observed within 30 to 60 seconds after the end of administration (administration should take 60 to 90 seconds). The doses for induction and maintenance vary depending upon species and preanesthetics. The duration of anesthesia varies depending upon species, dose, and preanesthetics. In dogs, the duration of anesthesia following the recommended induction dose (5.5 to 7.0 mg/kg without premedication) is generally 5 to 7 minutes. The duration of anesthesia after maintenance doses varies from 2 to 6 minutes following 1.1 mg/kg to 6 to 10 minutes following 3.3 mg/kg. Full standing recovery is generally observed within 10 to 20 minutes after the end of anesthesia, regardless of the duration of anesthesia. Recovery may be delayed in sighthounds or if preanesthetics are administered. In cats, the duration of anesthesia following the recommended induction dose (8.0 to 13.2 mg/kg without premedication) is generally 5 to 12 minutes. The duration of anesthesia after maintenance doses varies from 5 to 7 minutes following 1.1 mg/kg to 12 to 18 minutes following 4.4 mg/kg. Full standing recovery is generally observed within 30 to 45 minutes after the end of anesthesia, regardless of the duration of anesthesia. Recovery may be delayed if preanesthetics are administered.

Propofol Injectable Emulsion

PropofolVet Multidose is an anesthetic injection for use in dogs as follows: For induction of anesthesia. For maintenance of general anesthesia by intermittent bolus injections for short procedures. For induction of general anesthesia where maintenance is provided by inhalant anesthetics.

PropofolVet Multidose

Propofol is an intravenous anesthetic injection for use in dogs as follows: 1. For induction of anesthesia. 2. For maintenance of general anesthesia for up to 20 minutes. 3. For induction of general anesthesia where maintenance is provided by inhalant anesthetics.

PropoFloTM

PropofolVet Multidose (propofol injectable emulsion) is an intravenous sedative hypnotic agent for use in the induction and maintenance of anesthesia. Intravenous injection of propofol in the dog is followed by extensive metabolism of propofol in the liver to inactive conjugates which are excreted in the urine. Elimination from the central compartment occurs rapidly, with an initial elimination phase of less than 10 minutes. Induction of anesthesia will usually be observed within 65 to 120 seconds after the beginning of propofol administration. The duration of anesthesia following the recommended induction doses averages 5.5 to 6.5 minutes in preanesthetized and unpreanesthetized animals. The duration of anesthesia following recommended maintenance doses in unpreanesthetized dogs averages 8.5 minutes. In preanesthetized dogs (phenothiazine/opioid or benzodiazepine/opioid), maintenance anesthesia averages 5.0 to 5.4 minutes after each maintenance dose. Recovery from propofol is rapid; full standing recovery is generally observed within 20 minutes. The use of certain premedicants may result in prolonged recovery. Recovery may be delayed in Sighthounds. Propofol has been used in association with anticholinergics, phenothiazines, alpha2-agonists, opioids, and benzodiazepines, as well as inhalant anesthetics. No pharmacological incompatibility has been observed.

PropofolVet Multidose

Propofol injection is an intravenous sedative hypnotic agent for use in the induction and maintenance of anesthesia. Intravenous injection of propofol in the dog is followed by extensive metabolism of propofol in the liver to inactive conjugates which are excreted in the urine. Elimination from the central compartment occurs rapidly, with an initial elimination phase of less than 10 minutes1. Induction of anesthesia will usually be observed within 75-120 seconds after the beginning of propofol administration. The duration of anesthesia following the recommended induction doses averages 6.7 minutes in premedicated and unpremedicated animals. Recommended maintenance doses for anesthesia in unpremedicated animals, animals premedicated with acepromazine, and animals premedicated with a combination of agents results in anesthesia lasting an average of 3.68, 3.80 and 5.43 minutes, respectively, after each maintenance dose. Recovery from propofol is rapid; full standing recovery is generally observed within 20 minutes. The use of certain premedicant combinations (e.g., acepromazine/oxymorphone) may result in prolonged recovery. Recovery may be delayed in Sighthounds. Propofol has been used in association with atropine, glycopyrrolate, acepromazine, xylazine, oxymorphone, halothane and isoflurane. No pharmacological incompatibility has been observed.

PropoFloTM

After a single dose, propofol blood level profiles are characterized by a rapid distribution phase and a rapid elimination phase. The liver is the main site of metabolism with the major portion of metabolites being excreted in urine. No change in pharmacokinetics occurs after multiple daily dosing in dogs. Concomitant medication may affect the pharmacokinetics of either propofol or other medications. In dogs, propofol injectable emulsion injection has been used in association with acepromazine, atropine, glycopyrrolate, halothane, isoflurane, medetomidine, oxymorphone, and xylazine. No pharmacological incompatibility has been encountered. In cats, propofol injectable emulsion injection has been used in association with acepromazine, atropine, glycopyrrolate, butorphanol, oxymorphone, xylazine, and halothane. No pharmacological incompatibility has been encountered. To report suspected adverse drug events, call 1-855-724-3461. To obtain a copy of the Safety Data Sheet (SDS) or for technical assistance go to covetrus.com. For additional information about adverse drug experience reporting for animal drugs, Contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinarySafetyHealth.

Propofol Injectable Emulsion

After a single dose, propofol blood level profiles are characterized by a rapid distribution phase and a rapid elimination phase. The liver is the main site of metabolism with the major portion of metabolites being excreted in urine. No change in pharmacokinetics occurs after multiple daily dosing in dogs. Concomitant medication may affect the pharmacokinetics of either propofol or other medications. In dogs, Propovan™ CF injection has been used in association with acepromazine, atropine, glycopyrrolate, halothane, isoflurane, medetomidine, oxymorphone, and xylazine. No pharmacological incompatibility has been encountered. In cats, Propovan™ CF injection has been used in association with acepromazine, atropine, glycopyrrolate, butorphanol, oxymorphone, xylazine, and halothane. No pharmacological incompatibility has been encountered. To report suspected adverse drug events, call 1-888-621-0189. To obtain a copy of the Safety Data Sheet (SDS) or for technical assistance go to www.iavoes.com. For additional information about adverse drug experience reporting for animal drugs, Contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

VETONE® Propovan™ CF

Propofol injectable emulsion injection is contraindicated in dogs and cats with a known hypersensitivity to propofol or its components, or when general anesthesia or sedation are contraindicated.

Propofol Injectable Emulsion

Propovan™ 28 is contraindicated in dogs with a known hypersensitivity to propofol or its components, or when general anesthesia or sedation are contraindicated.

Propovan™ 28(propofol injectable emulsion)

Not for human use. Keep out of reach of children. Propofol injectable emulsion injection should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting. Rare cases of self-administration of propofol have been reported, including dose-related fatalities. Preventive care should be taken to avoid self-administration; for example, use of a guarded needle until the moment of injection is recommended. Symptoms of self-administration may include cardiovascular and/or respiratory depression. Anaphylaxis to propofol may occur during its first use, especially in patients with a history of drug allergy.7 In the event of accidental self-administration, seek medical attention immediately. Contact of this product with skin, eyes, and clothes should be avoided. If contact occurs, skin and eyes should be liberally flushed with water for 15 minutes. If irritation develops and continues, consult a physician. Initial arousal following propofol anesthesia can be extremely rapid. Caution should be used at this time in manipulations involving the mouth, such as removing an endotracheal tube.

Propofol Injectable Emulsion

Not for use in humans. Keep out of the reach of children. Rare cases of self-administration have been reported, including fatalities. PropofolVet Multidose should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting. Exercise caution to avoid accidental self-injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and/or apnea). Remove the individual from the source of exposure and seek medical attention. Respiratory depression should be treated by artificial ventilation and oxygen. Hypersensitivity reactions to propofol, including anaphylaxis, may occur in some individuals who are also allergic to muscle relaxants4. Avoid inhalation and direct contact of this product with skin, eyes, and clothes. In case of contact, eyes and skin should be liberally flushed with water for 15 minutes. Consult a physician if irritation persists.

PropofolVet Multidose

Induction of anesthesia with propofol injectable emulsion injection is frequently associated with apnea and respiratory depression. Hypotension and oxygen desaturation can occur also, especially following rapid bolus administration. Apnea is observed less frequently following maintenance doses of propofol injectable emulsion injection when given as the sole maintenance agent, or when a maintenance dose is administered during inhalant anesthesia. When using propofol injectable emulsion injection, patients should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. The clinical use of propofol without available supplemental oxygen and artificial ventilation has not been adequately evaluated and is not recommended.

Propofol Injectable Emulsion

Induction of anesthesia with Propovan™ CF injection is frequently associated with apnea and respiratory depression. Hypotension and oxygen desaturation can occur also, especially following rapid bolus administration. Apnea is observed less frequently following maintenance doses of Propovan™ CF injection when given as the sole maintenance agent, or when a maintenance dose is administered during inhalant anesthesia. When using Propovan™ CF injection, patients should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. The clinical use of propofol without available supplemental oxygen and artificial ventilation has not been adequately evaluated and is not recommended.

VETONE® Propovan™ CF

Rapid bolus administration (induction or maintenance) or accidental overdosage of propofol may cause undesirable cardiorespiratory depression including hypotension and oxygen desaturation. Respiratory arrest (apnea) could occur. In cases of respiratory depression, stop drug administration, establish a patent airway, and initiate assisted or controlled ventilation with pure oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other techniques as appropriate for the observed abnormality. When using propofol, dogs should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.

PropoFloTM 28

Rapid single or repeat bolus administration may cause undesirable cardiorespiratory depression including hypotension, apnea and oxygen desaturation. When using propofol, dogs should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.

PropoFloTM

Propofol undergoes oxidative degradation in the presence of oxygen and is therefore packaged under nitrogen to eliminate this degradation path. Store between 4 – 25°C (40-77°F). Do not freeze. Protect from light. Shake well before use.

PropoFloTM

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

PropoFloTM

The primary side effect of propofol injectable emulsion injection is respiratory depression and apnea. Apnea was observed in 20% of the dog cases in the clinical trial. Apnea was observed in 1.4% of the cat cases in the clinical trial. All apnea cases responded satisfactorily to oxygen supplementation and/or controlled ventilation. Apnea lasting less than 1 minute in healthy dogs or cats may cause no harm. Animals breathing atmospheric air that become apneic may show signs of cerebral damage after 2 minutes. Animals breathing 100% oxygen that become apneic may not show signs of cerebral damage for 5 to 8 minutes. Ventricular arrhythmias may occur secondary to hypoxia induced by apnea. The primary side effect of propofol injectable emulsion injection in cats is paddling during recovery. Paddling was observed in 11% of the cat cases in the clinical trial. Other transient side effects in dogs or cats are observed infrequently or rarely: - Respiratory: panting, reverse sneezing, cyanosis - Musculoskeletal: paddling during recovery, tremors, tenseness, movements, fasciculations - Cardiovascular: bradycardia, hypotension, cyanosis, tachycardia, premature ventricular contractions - Central Nervous System: excitation, opisthotonus, seizure - Injection Site: pain during injection - Gastrointestinal: emesis/retching - Other: rubbing at face or nose during recovery, vocalization during recovery, chewing or licking the injection site during recovery

Propofol Injectable Emulsion

The primary side effect of propofol is respiratory depression as evidenced by tachypnea and apnea. Tachypnea and apnea were observed in 43 and 26% of the cases in the clinical trial, respectively. All cases of apnea resumed normal breathing spontaneously, or responded satisfactorily to oxygen supplementation and/or controlled ventilation. Other transient side effects are observed infrequently or rarely: Respiratory: labored breathing Cardiovascular: hypotension, bradycardia, tachycardia, membrane cyanosis, arrhythmias Musculoskeletal: fasciculations, tenseness, paddling, movements Central Nervous System: excitation, opisthotonus, seizures, excessive depression Gastrointestinal: emesis, retching, salivation

PropoFloTM

The primary side effect of propofol is respiratory depression as evidenced by tachypnea and apnea. Other less frequent adverse reactions include: Respiratory: labored breathing Cardiovascular: hypotension, hypertension, bradycardia, tachycardia, membrane cyanosis, arrhythmias Musculoskeletal: fasciculations, tenseness, paddling, movements Central Nervous System: excitation, opisthotonos, seizures, excessive depression Gastrointestinal: emesis, retching, salivation.

PropoFloTM 28

Induction of General Anesthesia in Dogs: Induction dose guidelines are 4.0 to 6.5 mg/kg in dogs that do not receive a preanesthetic, and 1.4 to 6.5 mg/kg in dogs that receive a preanesthetic. The mean PROPOCLEAR induction dose is reduced by 20 to 30% for dogs that receive a preanesthetic (dose sparing effect). Anesthesia is usually observed within 60 seconds after the end of the induction dose administration. Duration of anesthesia following the recommended induction dose is approximately 4 minutes without a preanesthetic and 4 to 11 minutes with a preanesthetic. Individual anesthesia times may vary. Maintenance of General Anesthesia in Dogs: Anesthesia can be maintained by administration of PROPOCLEAR using intermittent IV injections. For dogs, the duration of anesthesia following a PROPOCLEAR maintenance dose is approximately 3 to 5 minutes. Clinical response may vary, and is determined by the dose, the rate of administration, and the frequency of maintenance injections. The maintenance dose and frequency should be based on the patient’s response. Sighthounds may need lower maintenance doses of PROPOCLEAR, and the time between maintenance dose administration and for recovery may be longer.

Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using propofol, patients should be continuously monitored and facilities for the maintenance of a patient airway, artificial ventilation, and oxygen supplementation must be immediately available.

PropoClear™

For induction of general anesthesia without the use of preanesthetics, the dosage is 7.6 milligrams per kilogram titrated against the response of the patient over 60-90 seconds or until clinical signs show the onset of anesthesia (5.0 to 7.6 mg/kg/min).The use of preanesthetic medication reduces propofol dose requirements. For the maintenance of general anesthesia without the use of preanesthetics, the dosage is 3.2 milligrams per kilogram The use of preanesthetic medication reduces propofol dose requirements. Due to the rapid metabolism of propofol, additional low doses of propofol, similar to those used for maintenance with propofol, may be required to complete the transition to inhalant maintenance anesthesia.

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Administer by intravenous injection only. Rapid bolus administration (induction or maintenance) or accidental overdosage of propofol may cause undesirable cardiorespiratory depression including hypotension and oxygen desaturation. Respiratory arrest (apnea) could occur. When using propofol, dogs should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. The use of propofol in pregnant and breeding dogs has not been evaluated. Propofol crosses the placenta and, as with other general anesthetic agents, the administration of propofol may be associated with neonatal depression. Propofol has not been evaluated in dogs less than 10 weeks of age

PropoFlo™ 28

For induction of general anesthesia without the use of preanesthetics, the dosage is 5.5 to 7.6 milligrams per kilogram (2.5 to 3.2 milligrams per pound)The use of preanesthetic medication reduces propofol dose requirements. For the maintenance of general anesthesia without the use of preanesthetics, the dosage is 2.2 to 3.2 milligrams per kilogram (0.5 to 1.5 milligrams per pound. The use of preanesthetic medication reduces propofol dose requirements.

Intravenous

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Administer by intravenous injection only. Rapid bolus administration (induction or maintenance) or accidental overdosage of propofol may cause undesirable cardiorespiratory depression including hypotension and oxygen desaturation. Respiratory arrest (apnea) could occur. When using propofol, dogs should be continuously monitored and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available. The use of propofol in pregnant and breeding dogs has not been evaluated. Propofol crosses the placenta and, as with other general anesthetic agents, the administration of propofol may be associated with neonatal depression. Propofol has not been evaluated in dogs less than 10 weeks of age

PropoFlo™

The drug is administered by intravenous injection as follows: For induction of general anesthesia without the use of preanesthetics the dosage is 5.5 to 7.0 milligrams per kilogram (2.5 to 3.2 milligrams per pound); for the maintenance of general anesthesia without the use of preanesthetics the dosage is 1.1 to 3.3 milligrams per kilogram (0.5 to 1.5 milligrams per pound). The use of preanesthetic medication reduces propofol dose requirements.

Intravenous

Adequate data concerning safe use of propofol in pregnant and breeding dogs have not been obtained. Doses may need adjustment for geriatric or debilitated patients.

Rapanofal®

Induction of General Anesthesia in Cats: Induction dose guidelines are 4.1 to 8.0 mg/kg for cats that do not receive a preanesthetic, and 2.7 to 8.0 mg/kg for cats that receive a preanesthetic. The PROPOCLEAR induction dose is reduced by 16 to 24% for cats that receive a preanesthetic (dose sparing effect). Anesthesia is usually observed within 60 seconds after the end of the induction dose administration. Duration of anesthesia following the recommended induction dose is approximately 3 minutes without a preanesthetic and 3 to 6 minutes with a preanesthetic. Full standing recovery occurs within approximately 30 minutes in cats. Individual anesthesia times vary. The actual induction dose should be based on patient response. Maintenance of General Anesthesia in Cats: Anesthesia can be maintained by administration of PROPOCLEAR using intermittent IV injections. For cats, the duration of anesthesia following each PROPOCLEAR maintenance dose is approximately 3 to 5 minutes. Clinical response may vary, and is determined by the dose, rate of administration and frequency of maintenance injections. PROPOCLEAR maintenance dose sparing is greater in cats that receive a preanesthetic. The maintenance dose and frequency should be based on the patient’s response.

Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using propofol, patients should be continuously monitored and facilities for the maintenance of a patient airway, artificial ventilation, and oxygen supplementation must be immediately available.

PropoClear™

The drug is administered by intravenous injection as follows: For induction of general anesthesia without the use of preanesthetics the dosage is 8.0 to 13.2 milligrams per kilogram (3.6 to 6.0 milligrams per pound). For the maintenance of general anesthesia without the use of preanesthetics the dosage is 1.1 to 4.4 milligrams per kilogram (0.5 to 2.0 milligrams per pound). The use of preanesthetic medication reduces propofol dose requirements.

Intravenous

Adequate data concerning safe use of propofol in pregnant and breeding cats have not been obtained. Doses may need adjustment for geriatric or debilitated patients. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Rapanofal®

For induction, PropofolVet Multidose should be titrated against the response of the patient over 60 to 90 seconds or until clinical signs show the onset of anesthesia. Rapid injection of propofol (≤5 seconds) may be associated with an increased incidence of apnea1. The average preserved propofol injectable emulsion induction dose rates for healthy dogs given propofol alone, or when propofol is preceded by a preanesthetic, are indicated in the table below. This table is based on field study results and is for guidance only. The dose and rate for propofol should be based upon patient response. Induction Dosage Guidelines Preanesthetic* Propofol Induction Dose Propofol Rate of Administration mg/kg Seconds mg/kg/min mL/kg/min None 7.6 60 to 90 5.0 to 7.6 0.50 to 0.76 Benzodiazepine/Opioid 4.7 60 to 90 3.1 to 4.7 0.31 to 0.47 Phenothiazine/Opioid 4.0 60 to 90 2.7 to 4.0 0.27 to 0.40 Alpha2-agonist/Opioid 3.2 60 to 90 2.1 to 3.2 0.21 to 0.32 *Doses for preanesthetics may be lower than the label directions for their use as a single medication2. The use of preanesthetics markedly reduces propofol requirements. Induction dose sparing was approximately 38% with benzodiazepine/opioid preanesthesia, 47% when dogs were preanesthetized with phenothiazine/opioid, and 58% when dogs were preanesthetized with alpha2-agonist. As with other sedative hypnotic agents, the amount of opioid and/or alpha2-agonist premedication will influence the response of the patient to an induction dose of propofol. In the presence of preanesthesia, the dose of propofol may be reduced with increasing age of the animal. The dose of propofol should always be titrated against the response of the patient. During induction, additional low doses of propofol, similar to those used for maintenance with propofol, may be administered to facilitate intubation or the transition to inhalant maintenance anesthesia.

INTRAVENOUS

PropofolVet Multidose

For induction, propofol injection should be titrated against the response of the patient over 30-60 seconds or until clinical signs show the onset of anesthesia. Rapid injection of propofol (≤ 5 seconds) may be associated with an increased incidence of apnea2. The average propofol induction dose rates for healthy dogs given propofol alone, or when propofol is preceded by a premedicant, are indicated in the table below. This table is for guidance only. The dose and rate should be based upon patient response. Induction Dosage Guidelines Preanesthetic Propofol Induction Propofol Rate of Administration Dose mg/kg Seconds mg/kg/min mL/kg/min None 5.5 40 - 60 5.5 - 8.3 0.55 - 0.83 Acepromazine 3.7 30 - 50 4.4 - 7.4 0.44 - 0.74 Acepromazine / Oxymorphone 2.6 30 - 50 3.1 - 5.2 0.31 - 0.52 Propofol doses and rates for the above premedicants were based upon the following average dosages. These doses may be lower than the label directions for their use as a single medication3,4. Dose (mg/kg) Routes Acepromazine 0.060 IM, SC, IV Oxymorphone 0.090 IM, SC, IV Xylazine 0.33 IM, SC The use of these drugs as preanesthetics markedly reduces propofol requirements. As with other sedative hypnotic agents, the amount of opioid and/or α-2 agonist premedication will influence the response of the patient to an induction dose of propofol. In the presence of premedication, the dose of propofol may be reduced with increasing age of the animal. The dose of propofol should always be titrated against the response of the patient. During induction, additional low doses of propofol, similar to those used for maintenance with propofol, may be administered to facilitate intubation or the transition to inhalant maintenance anesthesia. .

INTRAVENOUS

PropoFloTM

Administer by intravenous injection only. Shake the vial thoroughly before opening. Propofol is a white stable emulsion; do not use if there is evidence of separation of the phases. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing. Do not use if particulate matter and discoloration are present. Strict aseptic techniques must always be maintained during handling. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life threatening illness. Do not use if contamination is suspected. Once a vial is opened, the contents begin a 28-day shelf life. The opened vial should be labeled with “Date Opened” and “Use By” in the space provided. To avoid microbial overgrowth, the contents must be used within 28 days (4 weeks) of the date opened. The opened vial should be placed in a covered container, held at room temperature and used within the allotted 28 day timeframe. Refrigeration is not recommended. Any unused propofol remaining at the end of 28 days should be discarded. The emulsion should not be mixed with other therapeutic agents prior to administration. No specific preanesthetic is either indicated or contraindicated with propofol. The necessity for, choice of, as well as any necessary reduction of dose for the preanesthetic, is left to the discretion of the veterinarian. The dose of propofol is not affected by anticholinergic premedication.

INTRAVENOUS

PropoFloTM 28

A. Intermittent Propofol Injections: Anesthesia can be maintained by administering PropofolVet Multidose in intermittent IV injections. Clinical response will be determined by the amount and the frequency of maintenance injections. The following table is based on field study results and is provided for guidance: Maintenance Dosage Guidelines Preanesthetic* Propofol Maintenance Dose Propofol Rate of Administration mg/kg Seconds mg/kg/min ml/kg/min None 3.2 60 3.2 0.32 Benzodiazepine/Opioid 1.7 60 1.7 0.17 Phenothiazine/Opioid 2.0 60 2.0 0.20 *Doses for preanesthetics may be lower than the label directions for their use as a single medication2. Maintenance dose sparing was approximately 48% with benzodiazepine/opioid preanesthesia and 37% when dogs were preanesthetized with phenothiazine/opioid. Repeated maintenance doses of propofol do not result in increased recovery times or dosing intervals, indicating that the anesthetic effects of propofol are not cumulative. B. Maintenance by Inhalant Anesthetics: Due to the rapid metabolism of propofol, additional low doses of propofol, similar to those used for maintenance with propofol, may be required to complete the transition to inhalant maintenance anesthesia. Clinical trials using propofol have shown that it may be necessary to use a higher initial concentration of the inhalant anesthetic halothane than is usually required following induction using barbiturate anesthetics, due to rapid recovery from propofol3.

INTRAVENOUS

PropofolVet Multidose

Shake the vial thoroughly before opening. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Propofol is a white stable emulsion; do not use if there is evidence of separation of the phases. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing. Do not use if particulate matter and discoloration are present. Propofol contains no antimicrobial preservatives. Strict aseptic techniques must always be maintained during handling since the vehicle is capable of supporting the rapid growth of microorganisms. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life-threatening illness. Do not use if contamination is suspected. Once propofol has been opened, vial contents should be drawn into sterile syringes; each syringe should be prepared for single patient use only. Unused product should be discarded within 6 hours. The emulsion should not be mixed with other therapeutic agents prior to administration. Administer by intravenous injection only.

INTRAVENOUS

PropoFloTM

A. Intermittent Propofol Injections: Anesthesia can be maintained by administering propofol in intermittent IV injections. Clinical response will be determined by the amount and the frequency of maintenance injections. The following table is provided for guidance: Maintenance Dosage Guidelines Preanesthetic Propofol Maintenance Dose Rate of Administration mg/kg Seconds mg/kg/min mL/kg/min None 2.2 10 - 30 4.4 - 13.2 .044 - 1.32 Acepromazine 1.6 10 - 30 3.2 - 9.6 0.32 - 0.96 Acepromazine / Oxymorphone 1.8 10 - 30 3.6 - 10.8 0.36 - 1.08 Repeated maintenance doses of propofol do not result in increased recovery times or dosing intervals, indicating that the anesthetic effects of propofol are not cumulative. B. Maintenance by Inhalant Anesthetics: Due to the rapid metabolism of propofol, additional low doses of propofol, similar to those used for maintenance with propofol, may be required to complete the transition to inhalant maintenance anesthesia. Clinical trials using propofol have shown that it may be necessary to use a higher initial concentration of the inhalant anesthetic halothane than is usually required following induction using barbiturate anesthetics, due to rapid recovery from propofol5.

INTRAVENOUS

PropoFloTM

Shake the vial thoroughly before opening. Propofol injectable emulsion injection contains no antimicrobial preservatives. Strict aseptic techniques must always be maintained during handling since the vehicle is capable of supporting rapid growth of microorganisms. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life-threatening illness. Do not use if contamination is suspected. Propofol injectable emulsion injection should be prepared for use just prior to initiation of each individual anesthetic procedure. The vial rubber stopper should be disinfected using 70% isopropyl alcohol. The entire contents of the vial should be drawn into sterile syringes immediately after vials are opened. Administration should commence promptly and be completed within 6 hours after the vials are opened. Any unused product should be discarded within 6 hours. Administer by intravenous injection only. The emulsion should not be mixed with other therapeutic agents or injected into containers of infusion fluids prior to administration.

INTRAVENOUS

Propofol Injectable Emulsion

Shake the vial thoroughly before opening. Propovan™ CF (propofol) injection contains no antimicrobial preservatives. Strict aseptic techniques must always be maintained during handling since the vehicle is capable of supporting rapid growth of microorganisms. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life-threatening illness. Do not use if contamination is suspected. Propovan™ CF (propofol) injection should be prepared for use just prior to initiation of each individual anesthetic procedure. The vial rubber stopper should be disinfected using 70% isopropyl alcohol. The entire contents of the vial should be drawn into sterile syringes immediately after vials are opened. Administration should commence promptly and be completed within 6 hours after the vials are opened. Any unused product should be discarded within 6 hours. Administer by intravenous injection only. The emulsion should not be mixed with other therapeutic agents or injected into containers of infusion fluids prior to administration.

INTRAVENOUS

VETONE® Propovan™ CF